Recent Blog Posts

View Post: Molecular Cancer
Full text
Cytokeratin 8 ectoplasmic domain ... ...
View Blog: In this study we show that the monoclonal antibody that recognizes an epitope on the cytokeratin 8 (CK8) ectoplasmic domain (anti-CK MAb) inhibits plasminogen activation mediated by urokinase-type plasminogen activator (uPA) in MCF-7

---

View Post: Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In ...
17 Nov 2009
Riso Pharma guarantees to purchase 50000 KINLYTIC vials over next thr...TORONTO Nov. 17 / Microbix Biosystems Inc. (MB...Under the terms of the agreement Microbix will grant Riso exclusive r...Mark A. Cochran Microbix' Chief Business ...
View Blog: Latest Biology Technology from Bio-Medicine.Org - http://www.bio-medicine.org/biology-technology-1/

---

View Post: De-N-acetyl GM3 Promotes Melanoma Cell Migration and Invasion ...
11 Nov 2009 by Liu, J.-W., Sun, P., Yan, Q., Paller, AS,...  
Using metastatic (d-GM3–positive) and poorly invasive (d-GM3–negative) human melanoma cell lines, we found that d-GM3 stimulates cell migration and invasion by increasing the expression and activation of urokinase-like plasminogen ...
View Blog: Cancer Research current issue - http://cancerres.aacrjournals.org/

---

View Post: eScholarship: Direct interaction of the kringle domain of ...
1 Mar 2007 by Takehiko Tarui  
Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Multi-Campus: Retrieved from: ...
View Blog: eScholarship Repository - http://repositories.cdlib.org/

---

View Post: A Composite Role of Vitronectin and Urokinase in the Modulation of ...
23 May 2008 by Hillig, T., Engelholm, LH, Ingvarsen, S.,...  
The urokinase receptor, urokinase receptor (uPAR), is a glycosylphosphatidylinositol-anchored membrane protein engaged in pericellular proteolysis and cellular adhesion, migration, and modulation of cell morphology. ...
View Blog: Journal of Biological Chemistry current issue - http://www.jbc.org/

---

View Post: Blood -- Urokinase-type plasminogen activator increases hepatocyte ...
7 Oct 2009 by Sisson, T. H, Nguyen, M.-H., Yu, B., Novak,...  
Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Thomas H Sisson, Mai-Huong Nguyen, Bi Yu, Margaret L Novak, Richard H Simon, and Timothy J Koh* ...
View Blog: BLOOD First Edition Papers - http://bloodjournal.hematologylibrary.org/

---

View Post: Microbix Receives Approval To Market Thrombolytic Agent Kinlytic ...
10 Nov 2009 by Amit  
(MBX:TSX) today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the ...
View Blog: Generic Pharmaceuticals and Patents - http://genericspatent.blogspot.com/

---

View Post: Structure-based design of an urokinase-type plasminogen activator ...
17 Sep 2009 by Carriero, MV, Longanesi-Cattani, I., Bifulco,...  
The urokinase-type plasminogen activator receptor (uPAR) plays a central role in sustaining the malignant phenotype and promoting tumor metastasis. The Ser88-Arg-Ser-Arg-Tyr92 is the minimum chemotactic sequence of uPAR required to ...
View Blog: Molecular Cancer Therapeutics current issue - http://mct.aacrjournals.org/

---

View Post: Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In ...
17 Nov 2009 by Max  
Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing … PR Newswire (press release) Risks related to timeliness, delay or failure to obtain local market regulatory approvals or to enter into marketing and supply ...
View Blog: Affiliate Marketing - http://affiliatemarketing.wealthyboys.com/

---

View Post: Low-dose urokinase in massive pulmonary embolism when standard ...
8 Oct 2009 by Bulpa P, Carbutti G, Osselaer JC, Lawson...  
Therefore, prolonged lysis with low-dose urokinase (1000 units/kg/h) was initiated. After a few hours, the patients became hemodynamically stable and inotrope/vasopressor doses could be reduced and stopped. ...
View Blog: JournalFeeds - http://journalfeeds.com/

---